702 related articles for article (PubMed ID: 20473790)
21. Manipulation of the Innate Immune Response by Varicella Zoster Virus.
Gerada C; Campbell TM; Kennedy JJ; McSharry BP; Steain M; Slobedman B; Abendroth A
Front Immunol; 2020; 11():1. PubMed ID: 32038653
[TBL] [Abstract][Full Text] [Related]
22. [Varicella-zoster virus (VZV)].
Kanai K; Yamada S; Inoue N
Uirusu; 2010 Dec; 60(2):197-207. PubMed ID: 21488333
[TBL] [Abstract][Full Text] [Related]
23. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients.
van Besouw NM; Verjans GM; Zuijderwijk JM; Litjens NH; Osterhaus AD; Weimar W
J Med Virol; 2012 Dec; 84(12):2018-25. PubMed ID: 23080511
[TBL] [Abstract][Full Text] [Related]
24. Immune Responses to Varicella-Zoster Virus Vaccines.
Levin MJ; Weinberg A
Curr Top Microbiol Immunol; 2023; 438():223-246. PubMed ID: 35102438
[TBL] [Abstract][Full Text] [Related]
25. Varicella-zoster virus vaccine: molecular genetics.
Schmid DS
Curr Top Microbiol Immunol; 2010; 342():323-40. PubMed ID: 20225010
[TBL] [Abstract][Full Text] [Related]
26. IgM and IgG responses to varicella-zoster virus p32/p36 complex after chickenpox and zoster, congenital and subclinical infections, and vaccination.
Harper DR; Grose C
J Infect Dis; 1989 Mar; 159(3):444-51. PubMed ID: 2536788
[TBL] [Abstract][Full Text] [Related]
27. Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.
Perciani CT; Jaoko W; Walmsley S; Farah B; Mahmud SM; Ostrowski M; Anzala O; Team KI; MacDonald KS
BMJ Open; 2017 Sep; 7(9):e017391. PubMed ID: 28939581
[TBL] [Abstract][Full Text] [Related]
28. Quantification of a cell-mediated immune response against varicella zoster virus by assessing responder CD4
Haredy AM; Takei M; Iwamoto SI; Ohno M; Kosaka M; Hirota K; Koketsu R; Okuno T; Ikuta K; Yamanishi K; Ebina H
Vaccine; 2019 Aug; 37(36):5225-5232. PubMed ID: 31358406
[TBL] [Abstract][Full Text] [Related]
29. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation.
Wilson A; Sharp M; Koropchak CM; Ting SF; Arvin AM
J Infect Dis; 1992 Jan; 165(1):119-26. PubMed ID: 1309369
[TBL] [Abstract][Full Text] [Related]
30. Varicella-zoster virus-related neurological complications: From infection to immunomodulatory therapies.
Hakami MA; Khan FR; Abdulaziz O; Alshaghdali K; Hazazi A; Aleissi AF; Abalkhail A; Alotaibi BS; Alhazmi AYM; Kukreti N; Binshaya AS
Rev Med Virol; 2024 Jul; 34(4):e2554. PubMed ID: 38862398
[TBL] [Abstract][Full Text] [Related]
31. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.
Terada K; Niizuma T; Yagi Y; Miyashima H; Kataoka N; Sadahiro T
J Med Virol; 2000 Sep; 62(1):46-51. PubMed ID: 10935988
[TBL] [Abstract][Full Text] [Related]
32. Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections.
Levin MJ
J Clin Virol; 2014 Dec; 61(4):487-95. PubMed ID: 25453570
[TBL] [Abstract][Full Text] [Related]
33. The effect of vaccination on the epidemiology of varicella zoster virus.
Edmunds WJ; Brisson M
J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
[TBL] [Abstract][Full Text] [Related]
35. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection.
Arvin AM; Moffat JF; Sommer M; Oliver S; Che X; Vleck S; Zerboni L; Ku CC
Curr Top Microbiol Immunol; 2010; 342():189-209. PubMed ID: 20397071
[TBL] [Abstract][Full Text] [Related]
36. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
Trannoy E; Berger R; Holländer G; Bailleux F; Heimendinger P; Vuillier D; Creusvaux H
Vaccine; 2000 Feb; 18(16):1700-6. PubMed ID: 10689152
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation.
Jacquet A; Haumont M; Massaer M; Garcia L; Mazzu P; Daminet V; Grégoire D; Jacobs P; Bollen A
Vaccine; 2002 Feb; 20(11-12):1593-602. PubMed ID: 11858867
[TBL] [Abstract][Full Text] [Related]
38. Molecular and therapeutic aspects of varicella-zoster virus infection.
Quinlivan M; Breuer J
Expert Rev Mol Med; 2005 Aug; 7(15):1-24. PubMed ID: 16098235
[TBL] [Abstract][Full Text] [Related]
39. Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects.
Wittek AE; Arvin AM; Koropchak CM
J Clin Microbiol; 1983 Nov; 18(5):1146-9. PubMed ID: 6315766
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of CXCL10 in human dorsal root ganglia during experimental and natural varicella-zoster virus infection.
Steain M; Gowrishankar K; Rodriguez M; Slobedman B; Abendroth A
J Virol; 2011 Jan; 85(1):626-31. PubMed ID: 20980518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
